We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-5 of 5

Federal court rejects PMPRB Copaxone decision on excessive prices again

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 3 2013

By a decision of Justice Zinn dated April 30, 2013, the Federal Court quashed a Board's decision on excessive pricing of Copaxone - for the second

Court affirms utility of Gleevec patent

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • February 20 2013

"Sound prediction's introduction into Canadian law was not, as I understand it, to give a crushing hammer to those who challenge patents." Snider J

Gilead Sciences Canada, Inc. v. Canada (Minister of Health), 2012 FC 2, Complera (tenofovir, emtricitabine and rilpivirine), patent listing decision

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 3 2012

In this case the Court accepted the Minister’s position that a patent with combination patent claims and formulation claims to a triple medicinal ingredient product was not eligible for listing

Apotex Inc. v. Merck & Co. Inc., 2011 FCA 364 lovastatin; appeal from s.8 case

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 3 2012

In a decision is dated December 20, 2011 (but not released until recently), the Court of Appeal has overturned the Court’s finding that s. 8 of the 1993 NOC Regulations and found that the underlying NOC Regulation proceeding was “pending” at the time of the amendment of the NOC Regulations in 1998 as an appeal had been heard by the Supreme Court at that time and a decision was under reserve

Important recent trends in pharmaceutical patent litigation

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 28 2011

From a patentee’s perspective, the patent litigation landscape in 2010 and continuing into 2011 appears to have shifted to a more hospitable environment for innovators